Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

被引:0
|
作者
Day, D. [1 ,2 ]
Starus, A. [3 ]
Gebski, V. [4 ]
Simes, J. [4 ]
Hayes, T. [5 ]
Padinharakam, S. [6 ]
Strickland, A. H. [1 ,2 ]
Briscoe, K. [7 ]
Varma, S. [8 ]
Barnet, M. [9 ]
Jackson, C. [10 ]
Horvath, L. G. [11 ]
Price, T. J. [12 ,13 ]
Tebbutt, N. [14 ]
Karki, B. [15 ]
Diakos, C. I. [16 ]
Chia, J. [17 ]
Toh, H. C. [17 ]
Jones, F. S. [3 ]
Segelov, E. [18 ]
机构
[1] Monash Hlth, Dept Oncol, Clayton, Vic, Australia
[2] Dept Med, Clayton, Vic, Australia
[3] Sysmex Inost Inc, Med Affairs, Baltimore, MD USA
[4] Univ Sydney, NHMRC Clin Trial Ctr, Sydney, NSW, Australia
[5] Southwest Oncol, Med Oncol, Warrnambool, Vic, Australia
[6] Launceston Gen Hosp, Specialist Care Australia, Launceston, NSW, Australia
[7] Mid North Coast Canc Inst, Med Oncol, Coffs Harbour, NSW, Australia
[8] Townsville Hosp, Dept Oncol, Douglas, Qld, Australia
[9] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[10] Dunedin Publ Hosp, Dept Med Oncol, Dunedin, New Zealand
[11] Chris OBrien Lifehouse, Med Oncol, Camperdown, NSW, Australia
[12] Univ Adelaide, Med Oncol, Adelaide, SA, Australia
[13] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia
[14] Austin Hlth, Dept Oncol, Heidelberg, Vic, Australia
[15] Toowoomba Gen Hosp, Toowoomba Hosp Canc Ctr Serv, Clayton, Vic, Australia
[16] Genesis Care North Shore, Dept Med Oncol, St Leonards, NSW, Australia
[17] NCCS, Dept Med Oncol, Singapore, Singapore
[18] Univ Bern, Dept Clin Res, Fac Med, Bern, Switzerland
关键词
D O I
10.1016/j.annonc.2023.09.1777
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
586P
引用
收藏
页码:S426 / S427
页数:2
相关论文
共 50 条
  • [21] Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial
    Armstrong, A. J.
    Saad, F.
    Thiery-Vuillemin, A.
    Oya, M.
    Shore, N. D.
    Mehra, N.
    Ozguroglu, M.
    Gedye, C.
    Sartor, O.
    Poehlein, C. H.
    Qiu, P.
    Liu, Y-Z.
    Riva, L.
    Harrington, L.
    Barker, L.
    Del Rosario, P. M. D.
    Barnicle, A.
    Clarke, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1168 - S1168
  • [22] Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence
    Janni, Wolfgang
    Huober, Jens
    Braun, Tatjana
    Mueller, Volkmar
    Fink, Angelina
    de Gregorio, Amelie
    Rack, Brigitte
    Friedl, Thomas W.
    Wiesmueller, Lisa
    Pantel, Klaus
    Rich, Thereasa
    Parsana, Princy
    Zotenko, Elena
    Zhang, Shile
    Huesmann, Sophia
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for molecular residual disease (MRD) detection in surgical patients with stage I-IV colorectal cancer (CRC).
    Cao, Di
    Wang, Fu-Long
    Li, Cong
    Zhang, Rong-Xin
    Wu, Xiao-Jun
    Li, Liren
    Lu, Zhen-Hai
    Pan, Zhi-Zhong
    Lin, Jun-zhong
    Wu, Miaoqing
    Liu, Yifan
    Lv, Guangzhao
    Li, Min
    Wang, Chenyang
    Li, Xi
    Chen, Gong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 213 - 213
  • [24] A patient-specific, tumor-informed, circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assay in surgical patients with biliary tract cancer
    Song, Tianqiang
    Wu, Qiang
    Cui, Yunlong
    Li, Huikai
    Zhang, Wei
    Fang, Feng
    Xiong, Qingqing
    CANCER RESEARCH, 2023, 83 (07)
  • [25] Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer
    Janni, Wolfgang
    Friedl, Thomas
    Rack, Brigitte
    Fasching, Peter A.
    Hartkopf, Andreas
    Tesch, Hans
    Lorenz, Ralf
    Heinrich, Georg
    Blohmer, Jens-Uwe
    Fehm, Tanja
    Mueller, Volkmar
    Schneeweiss, Andreas
    Beckmann, Matthias
    Ruebner, Matthias
    Harbeck, Nadia
    Pantel, Klaus
    Dustin, Derek
    Cai, Mingyang
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases
    Vibat, Cecile Rose T.
    Melnikova, Vlada
    Minarik, Marek
    Belsanova, Barbora
    Hancock, Saege
    Hassaine, Latifa
    Samuelsz, Errin
    Lu, Timothy T.
    Erlander, Mark G.
    Benesova, Lucie
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Circulating tumour DNA (ctDNA) as a prognostic biomarker in patients (pts) with refractory metastatic colorectal cancer (mCRC) receiving TAS102 with or without bevacizumab
    Saoudi Gonzalez, N.
    Navarro Garces, V.
    Salva Ballabrera, F.
    Ros Montana, F. J.
    Baraibar Argota, I.
    Rodriguez Castells, M.
    Vaghi, C.
    Garcia Rodriguez, A.
    Alcaraz, A.
    Comas, R.
    Dienstmann, R.
    Tabernero, J.
    Vivancos, A.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S58 - S59
  • [28] Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice.
    Mehler, Shoshana
    Guilbeau, Seth
    Somer, Shmuel
    Reed, Kevin
    Greene, Heather
    Vaena, Daniel A.
    Grothey, Axel
    Somer, Brad
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)
    Isbell, James M.
    Goldstein, Jordan Scott
    Hamilton, Emily G.
    Liu, Si-Yang
    Eichholz, Jordan
    Buonocore, Darren J.
    Rusch, Valerie W.
    Bott, Matthew
    Molena, Daniela
    Rocco, Gaetano
    Yang, Soo-Ryum
    Rudin, Charles M.
    Jones, David R.
    Roff, Alanna
    Schultz, Andre
    Chabon, Jake J.
    Kurtz, David Matthew
    Alizadeh, Ash A.
    Li, Bob T.
    Diehn, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Utility of circulating tumor DNA (ctDNA) for detection of minimal residual disease (MRD) after curative-intent therapy in localized pancreatic cancer (PDAC)
    Yanala, Ujwal R.
    Martos, Mary
    Dickey, Erin M.
    Corona, Andres
    Ezenwajiaku, Nkiruka
    Pizzolato, Joseph
    Terrero, Gretel
    Hester, Caitlin A.
    Merchant, Nipun
    Hosein, Peter
    Datta, Jash
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S23 - S24